IDEAS home Printed from https://ideas.repec.org/a/bdz/joimer/v3y2024i3p1-6.html

Glucagon-Like Peptide-1 Receptor Agonist (GLP-1R): An Important Therapy to Treat Type 2 Diabetes

Author

Listed:
  • Devajit Mohajan

    (Department of Civil Engineering, Chittagong University of Engineering & Technology, Chittagong, Bangladesh)

  • Haradhan Kumar Mohajan

    (Department of Mathematics, Premier University, Chittagong, Bangladesh)

Abstract

The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone, and it has the ability to decrease blood sugar levels in a glucose-dependent nature to increase the secretion of insulin, and consequently, it reduces hyperglycaemia in T2D. GLP-1 has a half-life of about 1.5 minutes and is rapidly proteolytic degraded by dipeptidyl peptidase-4 (DPP-4). But GLP-1 receptor agonist (GLP-1R) works like GLP-1 but last much longer. GLP-1R control glycemia via glucose-dependent mechanisms of action and promote weight loss in obese and diabetic individuals. It also suppresses inappropriately elevated glucagon levels, both in fasting and postprandial states, slows gastric emptying, and decreases appetite. It reduces glycosylated hemoglobin (HbA1c) and fasting plasma glucose levels. It is associated with weight loss, and reductions in blood pressure with a low risk of hypoglycaemia. It is generally recommended as second- and third-line therapy for T2D. In this study an attempt has been taken to discuss aspects of GLP-1R in briefly.

Suggested Citation

  • Devajit Mohajan & Haradhan Kumar Mohajan, 2024. "Glucagon-Like Peptide-1 Receptor Agonist (GLP-1R): An Important Therapy to Treat Type 2 Diabetes," Journal of Innovations in Medical Research, Paradigm Academic Press, vol. 3(3), pages 1-6, September.
    • Handle: RePEc:bdz:joimer:v:3:y:2024:i:3:p:1-6
    DOI: 10.56397/JIMR/2024.09.01
    as

    Download full text from publisher

    File URL: https://www.paradigmpress.org/jimr/article/view/1253/1108
    Download Restriction: no
    File URL: https://libkey.io/10.56397/JIMR/2024.09.01?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Keywords

    ;
    ;
    ;
    ;

    JEL classification:

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bdz:joimer:v:3:y:2024:i:3:p:1-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Editorial Office (email available below). General contact details of provider: https://www.paradigmpress.org/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.